Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

BACKGROUND: Cancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer outpatients receiving chemotherapy. The aims of this retrospective analysis were to e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Barni, Sandro, Labianca, Roberto, Agnelli, Giancarlo, Bonizzoni, Erminio, Verso, Melina, Mandalà, Mario, Brighenti, Matteo, Petrelli, Fausto, Bianchini, Carlo, Perrone, Tania, Gasparini, Giampietro
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2011
Assuntos:
Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3220644/
https://ncbi.nlm.nih.gov/pubmed/22013950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-179
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares